Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going
Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the N...
Saved in:
Main Authors: | Eleanor Liu (Author), Nasar Aslam (Author), Gaurav Nigam (Author), Jimmy K Limdi (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Where we are, where we are going
by: Teresa Bermejo-Vicedo, et al.
Published: (2020) -
Pediatric Sepsis Research: Where Are We and Where Are We Going?
by: Letícia Massaud-Ribeiro, et al.
Published: (2022) -
Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
by: Giovanni Boscarino, et al.
Published: (2023) -
Colon Capsule Endoscopy: Where Are We and Where Are We Going
by: Yoo Min Han, et al.
Published: (2016) -
Where Are We Going?
by: Lloyd George, David, 1863-1945